Rheumatoid Arthritis Leukopak
LeukoCore Rheumatoid Arthritis Leukopak contains concentrated immune cells collected by IRB-approved leukapheresis from donors with clinically confirmed rheumatoid arthritis, an autoantibody-driven autoimmune disease. High cell numbers suit ACPA-reactive B cell work, CD4 T cell subset isolation, monocyte-to-osteoclast differentiation, and single-cell multi-omics. Donors can be stratified by ACPA and rheumatoid factor status, DAS28 activity, and treatment class.
LeukoCore Rheumatoid Arthritis Leukopak for Autoimmune and Immunology Research
LeukoCore Rheumatoid Arthritis Leukopak biospecimens are collected from IRB-consented donors clinically diagnosed with rheumatoid arthritis (RA) through IRB-approved apheresis procedures. Rheumatoid arthritis is a genuinely autoimmune disease: loss of tolerance to citrullinated self-proteins gives rise to anti-citrullinated protein antibodies (ACPA) and rheumatoid factor, and the resulting synovial inflammation destroys cartilage and bone. Each leukopak contains large quantities of peripheral blood mononuclear cells, supporting cell-intensive work in autoimmunity, B cell biology and bone destruction.
Why a Leukopak for Rheumatoid Arthritis Research
- ACPA and rheumatoid factor are produced by autoreactive B cells and plasmablasts that circulate at low frequency. Isolating and characterising antigen-specific B cells requires the cell numbers only apheresis can deliver.
- The strongest genetic risk in RA lies in the HLA-DRB1 shared epitope, which shapes presentation of citrullinated peptides to CD4+ T cells. Leukopaks provide enough CD4 T cells for antigen-specific and tetramer-based work in HLA-typed donors.
- Peripheral helper T cells and other B cell-helping T populations described in RA are rare subsets; recovering them in usable numbers for functional assays is a practical argument for leukopak rather than venipuncture collection.
- Bone erosion in RA is mediated by RANKL-driven osteoclasts differentiated from the monocyte lineage. A single leukopak supplies enough monocytes to generate osteoclasts in vitro and study erosive potential in patient-derived cells.
- RA is the disease in which TNF, IL-6 receptor, JAK, CD20 and CD28-costimulation blockade are all clinically established. Leukopak-scale material allows several mechanism-of-action readouts to be run in parallel on one donor rather than split across cohorts.
- High cell yields support engineered cell approaches — including regulatory T cell expansion and CAR-based tolerance strategies — that are increasingly explored in autoimmune disease.
Donor Stratification Available
- Serology: ACPA-positive, rheumatoid factor-positive, dual-positive, or seronegative RA
- Disease activity by DAS28 or CDAI where recorded
- Treatment status: biologic-naive, on methotrexate or other conventional synthetic DMARD, on TNF inhibitor, on IL-6 receptor inhibitor, on JAK inhibitor, on rituximab or abatacept, or in washout
- Disease duration: early versus established RA
- Erosive versus non-erosive disease where radiographic status is reported
- Extra-articular involvement and comorbidity, including interstitial lung disease
- Matched healthy controls available
Product Features
- Research Use Only (RUO) human leukopaks
- Clinically confirmed RA donors
- High cell yield for large-scale studies
- Processed and shipped within 24 hours of collection
- Fresh or cryopreserved options available
- IRB-approved and ethically sourced
- Infectious disease testing
- HLA-A typing
- Screen donors with LeukoLot™
De-identified Donor Data
- Verified RA diagnosis from healthcare providers
- Donor demographics: age, sex assigned at birth, race/ethnicity
- Self-reported medication history and allergies
- Serology and disease activity where available
- Relevant clinical data
Applications
- Autoreactive and antigen-specific B cell isolation and repertoire analysis
- CD4+ T cell subset isolation, including B cell-helping and peripheral helper populations
- Monocyte-derived osteoclast differentiation and bone resorption assays
- Mechanism-of-action studies for TNF, IL-6R, JAK, CD20 and costimulation-directed therapeutics
- Regulatory T cell expansion and engineered cell therapy development
- Cytokine profiling and cell-based functional assays
- Multi-omics studies including single-cell RNA sequencing and immune repertoire sequencing
- Immunophenotyping of seropositive versus seronegative RA
Other Rheumatoid Arthritis Specimen Types
- Rheumatoid Arthritis PBMC
- Rheumatoid Arthritis Serum
- Rheumatoid Arthritis Plasma
- Rheumatoid Arthritis Whole Blood
- Rheumatoid Arthritis Synovial Fluid
- Rheumatoid Arthritis Bulk Plasma
Compliance and Quality Assurance
- Collected under IRB oversight with donor e-consent (21 CFR Part 11 compliant)
- HIPAA-compliant handling of donor information
- Rigorous donor screening and documentation
Ordering & Customization
Rheumatoid Arthritis Leukopak is available fresh or cryopreserved. For pricing, current availability, or to discuss a serology-stratified cohort, contact learnmore@sanguinebio.com. Need a different condition, or want to check current availability across our full leukopak inventory? Visit our human leukopak page to browse other disease-state options and live stock status. For international shipping or regulatory documentation, please contact us to confirm regional compliance and shipping availability.
Protocols & Documentation
-
Download
Leukopak Cryopreservation
Standard operating procedure for cryopreserving leukopak units with controlled freezing and post-thaw viability targets.
-
Download
Leukopak Thawing
Validated thawing workflow for cryopreserved leukopaks to maximize recovery while maintaining sterility and chain of custody.
-
Download
Choosing the Right PBMC Configuration
Reference guide comparing PBMC formats, cryopreservation states, and study-fit recommendations for your application.
-
Informed Consent Form (ICF)
Available upon request — confirms donor consent for research use and downstream commercialization.
Leukopak
Frequently Asked Questions
1 Answer
YES – All collections are conducted under IRB-approved protocols and electronic informed consent. Sanguine utilizes Advarra and WCG IRB for oversight.
1 Answer
YES – all our products are research use only (RUO).
1 Answer
You can find our full product catalog here.
1 Answer
Storage depends on sample type but often cryopreserved samples stored in liquid nitrogen can be stored for years.
1 Answer
Extensive customization is available. To discuss your project request a quote or email us at learnmore@sanguinebio.com.
1 Answer
Sanguine offers flexible prospective collection services tailored to fit your research. For more information and to request a quote, please see: our prospective biospecimen collection services page.
1 Answer
Timelines depend on condition, sample type, and I/E criteria but we often start collection within 2 weeks of signed agreement.
1 Answer
YES – we have in-stock inventory. You can also email us at learnmore@sanguinebio.com as we continually get new samples in our inventory.
1 Answer
Each sample from a different individual – Unique donor means each sample comes from a different person, ensuring biological diversity in your study.
1 Answer
YES – Unique donors can be specified and guaranteed based on your requirements.
1 Answer
For information about sample quality, please see: Quality and Compliance
1 Answer
YES – “IRB-approved collection protocols” and IRB approval documentation available upon request. Sanguine utilizes two internationally-recognized IRBs (Advarra and WCG IRB) for review and approval.
Ask a Question
Need a custom Leukopak cohort?
Our scientific team can scope prospective collections with donor-specific I/E criteria, typically starting within 2 weeks of agreement.